MALVERN, Pa. -- Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC's methyltransferase screens from 14 to 35 or more.

NEW YORK CITY, N.Y. -- As Mark Whitacre, COO of Cypress Systems, Inc., walked the red carpet on September 15 during the premiere of...

CLEVELAND, Ohio /eNewsChannels/ -- NEWS: Ohio's Lakewood College today announced a new payment plan option that will allow students to graduate from the Pharmacy Technician Certificate Program without going thousands of dollars into debt. Lakewood College is committed to helping students achieve their goals affordably.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 at 11:15 am, Dr. Hall will present the scientific principles, clinical validation, and global development status of the company's innovative tumor-targeting technology embodied in its lead product, Rexin-G, the first targeted genetic medicine developed to treat metastatic cancer.

NEW YORK, N.Y. and LONDON, England -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry. On Wednesday 26 March 2008, Dr. Bates will deliver a presentation titled, "Are You Up to the Challenge of Measuring ROI in Changing Dynamics of the Pharma Industry?"

NEWS: Philosys, Inc., the maker of Gmate(R) products, announced today that the U.S. Food and Drug Administration (FDA) has approved clearance for the Gmate SMART Blood Glucose Monitoring System and App for Android(TM). The Gmate SMART is a small, portable blood glucose meter that plugs into the headphone jack of a smartphone and provides fast and accurate blood glucose test results.

SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted...

NEW YORK, N.Y. -- Eularis is announcing the release of an update to its report "Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web...

NEWS: Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.

HUNTINGTON BEACH, Calif. /eNewsChannels/ -- NEWS: SignatureCLL today announced that the first laboratory test ever shown in a clinical trial to improve one year survival rates in cancer is now available to patients with chronic lymphocytic leukemia (CLL). The U.S. cancer physician who invented the test and the British scientist who used it to make discoveries in leukemia will offer the test under the trade name SignatuRx through their own, newly-formed laboratory company.